Abstract
There is a high demand for new drugs against malaria, which takes millions of lives annually. The abuse of classical antimalarials from the late 1940's to the early 1980's has bred resistant parasites, which led to the use of more potent drugs that ended up by refueling the resistance cycle. An example is chloroquine, once highly effective but now virtually useless against malaria.
Structure-based rational drug design relies on high-resolution target structures to allow for screening of selective ligands/inhibitors. For the past two decades, and especially after the unveiling of the Plasmodium falciparum genome in 2002, enzymes of this lethal malaria parasite species have been increasingly attracting the attention of Medicinal Chemists worldwide as promising drug targets. There is particular emphasis on proteases having key roles on the degradation of host's hemoglobin within the food vacuole of blood-stage parasites, as these depend on such process for their survival. Among such enzymes, Plasmepsins (aspartic proteases) and, especially, Falcipains (cysteine proteases) are highly promising antimalarial drug targets. The present review will focus on the computational approaches made so far towards the unraveling of the structure, function and inhibition of Falcipains that, by virtue of their quite specific features, are excellent targets for highly selective inhibitors.
Keywords: Cysteine proteases, drug design, falcipain inhibitors, falcipains, malaria, Plasmodium Falciparum, classical antimalarials, resistant parasites, chloroquine
Current Medicinal Chemistry
Title: Falcipains, Plasmodium falciparum Cysteine Proteases as Key Drug Targets Against Malaria
Volume: 18 Issue: 10
Author(s): C. Teixeira, J. R.B. Gomes and P. Gomes
Affiliation:
Keywords: Cysteine proteases, drug design, falcipain inhibitors, falcipains, malaria, Plasmodium Falciparum, classical antimalarials, resistant parasites, chloroquine
Abstract: There is a high demand for new drugs against malaria, which takes millions of lives annually. The abuse of classical antimalarials from the late 1940's to the early 1980's has bred resistant parasites, which led to the use of more potent drugs that ended up by refueling the resistance cycle. An example is chloroquine, once highly effective but now virtually useless against malaria.
Structure-based rational drug design relies on high-resolution target structures to allow for screening of selective ligands/inhibitors. For the past two decades, and especially after the unveiling of the Plasmodium falciparum genome in 2002, enzymes of this lethal malaria parasite species have been increasingly attracting the attention of Medicinal Chemists worldwide as promising drug targets. There is particular emphasis on proteases having key roles on the degradation of host's hemoglobin within the food vacuole of blood-stage parasites, as these depend on such process for their survival. Among such enzymes, Plasmepsins (aspartic proteases) and, especially, Falcipains (cysteine proteases) are highly promising antimalarial drug targets. The present review will focus on the computational approaches made so far towards the unraveling of the structure, function and inhibition of Falcipains that, by virtue of their quite specific features, are excellent targets for highly selective inhibitors.
Export Options
About this article
Cite this article as:
Teixeira C., R.B. Gomes J. and Gomes P., Falcipains, Plasmodium falciparum Cysteine Proteases as Key Drug Targets Against Malaria, Current Medicinal Chemistry 2011; 18 (10) . https://dx.doi.org/10.2174/092986711795328328
DOI https://dx.doi.org/10.2174/092986711795328328 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Flexibility and Ligand Recognition: Challenges for Molecular Modeling
Current Topics in Medicinal Chemistry Effects of Exercise on Anxiety and Depression Disorders: Review of Meta- Analyses and Neurobiological Mechanisms
CNS & Neurological Disorders - Drug Targets First Detection of Tobacco Mosaic Virus in Tobacco Fields in Northern Lebanon
Infectious Disorders - Drug Targets Type 2 Transglutaminase in Neurodegenerative Diseases: The Mitochondrial Connection
Current Pharmaceutical Design Homotrimeric dUTPases; Structural Solutions for Specific Recognition and Hydrolysis of dUTP
Current Protein & Peptide Science Unusual Food Allergy: AlioideaAllergic Reactions Overview
Recent Patents on Inflammation & Allergy Drug Discovery Application of VEGF Gene Therapy in Two Basic Fields of Plastic- Reparative Surgery: Tissue Reconstruction with Flaps and Peripheral Nerve Surgery
Recent Patents on Regenerative Medicine Histamine H3 Receptor Function and Ligands: Recent Developments
Mini-Reviews in Medicinal Chemistry Utilization of the DaT-SCAN SPECT in the Diagnosis of Parkinson's Disease in Older Subjects
Letters in Drug Design & Discovery A Dig Deep to Scout the Pharmacological and Clinical Facet of Garlic (<i>Allium sativum</i>)
Current Traditional Medicine Changing Paradigm from one Target one Ligand Towards Multi-target Directed Ligand Design for Key Drug Targets of Alzheimer Disease: An Important Role of In Silico Methods in Multi-target Directed Ligands Design
Current Neuropharmacology Factors of Rapid Cognitive Decline in Late Onset Alzheimer's Disease
Current Aging Science Clinical Applications of MAO-Inhibitors
Current Medicinal Chemistry Bone: A Fertile Soil for Cancer Metastasis
Current Drug Targets In Silico Validation for the Modulatory Effect of Tea Catechins on Erythrocyte Na<sup>+</sup>/K<sup>+</sup>-ATPase
The Natural Products Journal Cholinergic Treatment of Traumatic Brain Injury
Current Drug Therapy Hypothesis-Driven Medication Discovery for the Treatment of Psychostimulant Addiction
Current Drug Abuse Reviews Colchicine Protects Dopaminergic Neurons in a Rat Model of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Electroporation Advances in Large Animals
Current Gene Therapy PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design